rawfin.tv
CVS Caremark Reinstates Zepbound Coverage After Patient Backlash
RegulationstocksAI Generated

CVS Caremark Reinstates Zepbound Coverage After Patient Backlash

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

CVS Caremark announced it will resume covering Eli Lilly's weight loss drug Zepbound following significant patient backlash. The decision reverses an earlier move to remove the drug from its list of covered medications.

pharmaceuticalshealthcaredrug-coverageCVSEli-Lilly

Related Articles

China Equities Lag US Stocks by Record 2.095 Valuation Ratio

China Equities Lag US Stocks by Record 2.095 Valuation Ratio

stocks
S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

stocks
Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

stocks
Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

stocks